Aktuellt
SENASTE
Redeye endorses yesterday’s news that Alzecure has chosen a candidate drug for its second project within the preventive Alzheimer’s platform Alzstatin, ACD680. The candidate drug will now be evaluated in the pre-clinical stage. Alzecure states that this builds on the company’s strategy to develop several candidates in tandem, in order to choose the optimal candidate for clinical development. ACD680, for example, has a more attractive patent life. We expect further progress with Alzstatin this year and will likely dig deeper into the platform once it is getting closer to the clinic.
LÄS MER
